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Propofol sedation without endotracheal
intubation is safe for endoscopic submucosal
dissection in the esophagus and stomach
SEM van de Ven1 , L Leliveld2, M Klimek2, TRH Hilkemeijer2, MJ Bruno1 and
AD Koch1
Abstract
Background: Endoscopic submucosal dissection (ESD) for early esophageal and stomach cancer is usually performed under
general anesthesia. However, propofol sedation without endotracheal intubation has been suggested as a viable alternative.
Objective: The objective of this study was to evaluate the safety of propofol sedation without endotracheal intubation during
ESD in the upper gastrointestinal tract.
Methods: We performed a retrospective cohort study of patients who underwent ESD for upper gastrointestinal tumors with
propofol-remifentanil analgosedation in a tertiary referral center in the Netherlands between October 2013 and February
2018. Primary endpoints were the rates of intraprocedural endoscopy- and anesthesia-related complications. Secondary
endpoints were the postprocedural complication rates within 30 days and endotracheal intubation conversion rates.
Results: Of 88 patients, intraprocedural ESD-related complications occurred in three patients (3.4%). Intraprocedural
anesthesia-related complications occurred in two patients (2.3%), one of whom required conversion to endotracheal
intubation. Postprocedural ESD-related complications occurred in 14 patients (15.9%), and minor postprocedural compli-
cations occurred in two patients (2.3%). Eighty-two (93.2%) patients were discharged within one day after ESD. No patient
was readmitted for anesthesia-related complications.
Conclusion: Propofol-based sedation without endotracheal intubation is safe for ESD procedures in the esophagus and
stomach with low anesthesia-related complication rates and short hospital stay.
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Key summary
. Appropriate sedation and analgesia are required during endoscopic submucosal dissection (ESD) in the
esophagus and stomach to limit complications.
. Most ESDs are performed under general anesthesia with endotracheal intubation for continuous airway
protection.
. We performed ESD with propofol sedation without endotracheal intubation. Anesthesia-related compli-
cations were low (2.3%); only one patient required conversion to endotracheal intubation.
. A total of 93.2% of the patients were discharged within one day after ESD.
. Propofol sedation without endotracheal intubation is safe and feasible for ESD.
Introduction
Endoscopic submucosal dissection (ESD) is a widely
used endoscopic resection method for early gastric
and esophageal neoplasms that cannot be removed
by endoscopic mucosal resection (EMR) or when
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submucosal invasion is suspected.1,2 ESD enables en
bloc resection of the lesion and has a higher curative
resection rate than EMR.3–5 However, ESD is diﬃcult
and time consuming and can result in pain and discom-
fort for the patient during the procedure.3,6 Minimal
patient movement is preferred, as ESD involves com-
plex and precise maneuvers.7 Therefore, appropriate
sedation and analgesia are required to limit complica-
tions, such as bleeding or perforation.7–9
Several types of (analgo-) sedation have been used
during ESD, ranging from conscious sedation
using midazolam or propofol to general anesthesia.10–12
The advantages of propofol over midazolam as a seda-
tive agent are clearly established: fewer movements of
the patient during ESD and faster recovery after the
procedure because of the short half-life of propo-
fol.10,13–17 Propofol provides stable sedation, and as a
result, patients do not experience any restless-
ness.8,10,13–15,18 Combining remifentanil with propofol
as analgosedation improves intraoperative hemo-
dynamic control during painful procedures compared
with fentanyl, which is mostly used in combination with
midazolam.19 Nowadays, most ESDs are performed
under general anesthesia with endotracheal intub-
ation.12,20–22 Aspiration in the course of long-lasting pro-
cedures or due to intraprocedural bleeding is a feared
complication. The beneﬁt of general anesthesia is con-
tinuous airway protection, which may lead to fewer
respiratory problems and interruptions during the pro-
cedure and therefore fewer endoscopy- and anesthesia-
related complications.7,12,23 The downsides of general
anesthesia are prolonged postprocedural hospital stay,
the need for an anesthesiologist, additional logistic chal-
lenges and higher procedural costs.7,12
Currently, there are no guideline recommendations
regarding the preferred sedation method during ESD in
the esophagus and stomach. We have used propofol-remi-
fentanil analgosedation without endotracheal intubation
for ESD in our center since October 2013. In general, in
the Netherlands, propofol sedation can be performed by a
sedation practitioner (SP) specialized in procedural sed-
ation without the need for an anesthesiologist.24
We hypothesize that ESD can be safely performed
with analgosedation using propofol and remifentanil
without endotracheal intubation with low endoscopy-
and anesthesia-related complication rates. The aim of
this study was to report on endoscopy- and anesthesia-
related complications of ESDs in the upper gastrointes-
tinal tract to determine the safety of propofol sedation
without endotracheal intubation.
Materials and methods
We retrospectively reviewed the medical records of
all consecutive patients who were treated with ESD
for upper gastrointestinal tumors using propofol-
remifentanil analgosedation in a tertiary referral
center between October 2013 and February 2018.
The study was approved by the medical ethical review
committee (MEC-2018-1060).
Anesthesia management
Analgosedation was administered before and during
ESD by an SP specialized in procedural sedation
(L.L.). The SP is a registered anesthesia nurse having
followed an additional theoretical and practical, specia-
list-supervised training. The SP is responsible for the
sedation of the patient and is trained to manage poten-
tial medical complications of sedation such as airway
and cardiovascular changes. The SP is competent in
advanced life-support skills and airway management
and understands the pharmacology of the drugs used.
The SP is supervised by an anesthesiologist, who is not
present in the endoscopy room but on call if necessary.
Patients were continuously sedated with intravenous
injection of 1%–2% propofol emulsion at a dose of
1–7mg/kg/hour to achieve a Ramsay Sedation Scale
(RSS) score 4 (Table 1). Analgesia was obtained
with intravenous injection of remifentanil, starting at
a dose of 2–9 mg/kg/minute. Additional medications
that could be administered during the procedure were
glycopyrronium (reduction of mucus secretion), scopol-
amine butyl (reduction of spasms of the gastrointestinal
tract), esketamine (anesthetic), granisetron (anti-
emetic), dexamethasone (antiemetic and analgesic)
and piritramide (analgesic). Supplemental oxygen was
administered via nasal cannula with CO2 monitoring.
Heart activity (including ﬁve- or six-lead electrocardi-
ography), respiratory rate and RSS were continuously
monitored. Blood pressure was monitored every ﬁve
minutes. Ephedrine or low-dose norepinephrine was
administered in case of low blood pressure and atropine
in case of bradycardia. Oxygen ﬂow was increased
if desaturation occurred until saturation level >95%
was achieved.
Table 1. Ramsay Sedation Scale.
1 Patient is anxious and agitated or restless, or both.
2 Patient is cooperative, oriented, and tranquil.
3 Patient responds to command only.
4 A brisk response to a light glabella tap or loud auditory
stimulus.
5 A sluggish response to a light glabella tap or loud auditory
stimulus.
6 No response to a light glabella tap or a loud auditory
stimulus.
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Sedation parameters were collected from the anes-
thesiology patient data management system, including
anesthesia duration, medications used, and complica-
tions. Anesthesia duration was deﬁned as the time
between the start of propofol sedation until patient’s
awakening (RSS of 2).
ESD
All ESDs were performed by a single endoscopist
(A.K.), an interventional endoscopist specializing in
ESDs. ESD involved marking of the lesion, circumfer-
ential mucosal incision and submucosal dissection
with simultaneous hemostasis. After circumferential
marking of the lesion, a saline solution containing epi-
nephrine (0.01mg/ml) and indigo carmine was injected
into the submucosal layer underneath the lesion to
elevate the lesion from the muscular layer. A circum-
ferential incision was made in the mucosa using a
HybridKnife (ERBE Elektromedizin GmbH,
Tuebingen, Germany) and the submucosal layer was
dissected until the lesion was completely resected.
All specimens were reviewed by an expert gastrointes-
tinal pathologist and classiﬁed according to the Vienna
classiﬁcation of gastrointestinal neoplasia.25
Data extraction
Patient characteristics such as age, gender, use of anti-
coagulation, American Society of Anesthesiologists
classiﬁcation and clinical follow-up were collected
from patient medical charts. Endoscopy characteristics
such as location of the lesion, Paris classiﬁcation, lesion
size, accomplishment of en bloc resection (deﬁned as a
macroscopic complete resection of the lesion in a single
specimen), intraprocedural ESD-related complications,
and duration of the procedure (deﬁned as the time
between the introduction and removal of the endo-
scope) were collected from endoscopy reports.
Complications
Intraprocedural anesthesia-related complications were
deﬁned as oxygen desaturation (SpO2< 90%), hypo-
tension (systolic blood pressure <80mmHg), bradycar-
dia (heart rate <50 bpm), apnea or coughing during
the procedure that caused an interruption of the pro-
cedure or conversion to endotracheal intubation.
Intraprocedural ESD-related complications were
deﬁned as adverse events (e.g. bleeding or perforation)
that caused a change of procedure management, such
as discontinuation of ESD. Postprocedural complica-
tions comprised all adverse events that resulted in pro-
longed hospital stay, hospital readmission or additional
medical interventions within 30 days.
Statistical analysis
Categorical data are presented as frequencies and per-
centages. Continuous data are presented as mean
(range) and median (interquartile range (IQR)) for
normally distributed and skewed data, respectively.
Analysis was carried out using IBM SPSS version 24.
Results
A total of 97 ESDs were performed in 96 patients
between October 2013 and February 2018 (Figure 1).
Three patients received general anesthesia during ESD.
In two patients, the procedure was combined with other
surgical procedures. In the other patient, the lesion was
located near the upper esophageal sphincter, necessitat-
ing endotracheal intubation. In three patients midazo-
lam was used as a sedative because procedural time and
anticipated technical challenges in relation to small
lesion size were estimated to be minimal. Anesthesia
reports were missing in three patients. These nine
patients were excluded from further analysis. A total
of 88 ESDs in 87 patients were included in the
ﬁnal analysis.
ESD was performed in the esophagus (34/88;
38.6%), stomach (53/88; 60.2%) and duodenal bulb
(1/88; 1.1%) (Figure 1). Baseline characteristics are out-
lined in Table 2. Median endoscopic procedure time
was 100 minutes (IQR: 65–139) and median anesthesia
sedation time was 125 minutes (IQR 97–166). Median
dose given during the procedure was 403mg (IQR
272–691) for propofol and 552mg (IQR 351–552) for
remifentanil.
ESD
(Oct 2013 – Feb 2018)
(N =97)
ESD with propofol
(N =91)
Total included ESD
with propofol 
(N =88)
Esophagus (N =34)
Stomach (N =53)
Duodenal bulb (N =1)
Exclusion (N =6)
General anesthesia;
• combination with surgery (N =2)
• lesion in the cervical area (N =1)
Midazolam sedation (N =3)
Missing anesthesia report
(N =3)
Figure 1. Flowchart of study inclusion.
ESD: endoscopic submucosal dissection.
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Tumor characteristics
Tumor characteristics are outlined in Table 3. In seven
patients (8.0%), the procedure was discontinued and no
histology was obtained (muscular invasion: 5, bleeding:
2). The pathology report was missing for one patient,
leaving 80 reports available for analysis. En bloc resec-
tion rate was 91% and piecemeal resection was per-
formed in one patient (1.1%). Early cancer was found
in 75/80 lesions (94%).
ESD-related complications
The complication rate was calculated for 88 ESD pro-
cedures (Table 4). Intraprocedural complications were
reported in three procedures (3.4%; all bleeding). In
one patient, ESD was converted to EMR and the bleed-
ing was successfully treated with coagulation. In the
other two patients, ESD was discontinued and no hist-
ology was obtained. One patient received surgical resec-
tion, the other patient received chemoradiotherapy as
surgical resection was deemed not feasible because of
extensive comorbidity. A postprocedural ESD-related
complication occurred in 14 patients (15.9%). Six
patients developed retrosternal pain for which three
patients were given analgesic medication during pro-
longed hospitalization. One patient was hospitalized
one extra day without requiring additional analgesics.
A re-endoscopy was performed in two of six patients.
In one patient, re-endoscopy after 24 days showed a
normal healing ulcer that was treated with sucralfate.
The other patient showed candidiasis on re-endoscopy
after seven days that was treated with ﬂuconazole. In
both patients, no explanation for retrosternal pain was
found. Five patients suﬀered from delayed bleeding.
Re-endoscopy was performed in three of these ﬁve
patients: two without any intervention and one with
clip placement for a bleeding ulcer. In two patients,
delayed bleeding resulted in prolonged hospitalization
without requiring additional intervention. Three
patients with delayed bleeding were on anticoagulation
Table 4. Complications (n¼ 88).
N (%)
Anesthesia-related complications
Intraprocedural
Coughing 1 (1.1)
Hypotensionþ desaturation 1 (1.1)
Total 2 (2.2)
ESD-related complications
Intraprocedural
Bleeding 3 (3.4)
Postprocedural
Retrosternal pain 6 (6.8)
Delayed bleeding 5 (5.7)
Stomach pain 1 (1.1)
Dysphagia 2 (2.3)
Total 14 (15.9)
Other postprocedural complications
Nausea 1 (1.1)
Atrial fibrillation 1 (1.1)
Total 2 (2.2)
ESD: endoscopic submucosal dissection.
Table 2. Baseline characteristics of 87 patients.
N (%) Median (IQR)
Age 70 (60–76)
Sex
Male 51 (58.6)
Female 36 (41.4)
BMI (kg/m3) 26.3 (22.9–28.7)
ASA score
I 10 (11.5)
II 45 (51.7)
II 32 (36.8)
Anticoagulant therapy
Yes 34 (39.1)
No 53 (60.9
Type of anticoagulant therapy
Antiplatelet drugs 16 (47.1)
Vitamin K antagonist 17 (50.0)
Othera 1 (2.9)
ASA: American Society of Anesthesiologists; BMI: body mass index; IQR:
interquartile range.
aDabigatran.
Table 3. Tumor characteristics (n¼ 80).
N (%) Median (IQR)
Histology
Adenocarcinoma 42 (52.5)
Squamous cell carcinoma 18 (22.5)
Neuroendocrine tumor 1 (1.3)
Gastrointestinal stromal cell tumor 8 (10.0)
High-grade dysplasia 6 (7.50)
Low-grade dysplasia 1 (1.3)
No malignancy 4 (5.0)
R0 resection
Yes 56 (70.0)
No 17 (21.3)
Unknown 7 (8.7)
Tumor size, diameter (mm) 30 (20–40)
IQR: interquartile range.
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therapy, which was discontinued before the procedure.
Bleeding occurred after anticoagulation therapy was
restarted. Additional postprocedural ESD-related com-
plications were dysphagia (two patients, reendoscopy
with esophageal dilation) and gastric pain (one patient,
prolonged hospitalization without intervention).
Anesthesia-related complications
An intraprocedural anesthesia-related complication
occurred in two patients (2.3%). One patient coughed,
causing a deep laceration in the muscular layer, which
was treated with clip placement. The other patient
suﬀered from hypotension and desaturation after a
procedure of more than ﬁve hours. The anesthesia tech-
nique was converted to general anesthesia with endo-
tracheal intubation, and the endoscopic procedure was
completed successfully. No postprocedural anesthesia-
related complication was observed.
Two postprocedural complications were not clearly
anesthesia or ESD related. One patient experienced
nausea directly after the procedure, which could be
caused by intragastric blood or by sedation with pro-
pofol. Nausea disappeared shortly after antiemetic
therapy was given. One patient showed atrial ﬁbrilla-
tion several hours after the procedure. No clear connec-
tion could be established between atrial ﬁbrillation
and propofol sedation; the patient was known to have
paroxysmal atrial ﬁbrillation. Both patients were dis-
charged the day after the procedure.
Hospital stay
Overall, the mean hospital stay after ESD was 0.9 days
(2.6). Almost half of the patients were discharged
the same day as the procedure (43 patients, 48.9%).
Thirty-nine patients (44.3%) were discharged the fol-
lowing day: 23 for logistic reasons and 16 for medical
reasons. In six patients, hospital stay exceeded two
days. No patient was readmitted for anesthesia-related
complications.
Discussion
In this retrospective, observational cohort study, we
found that ESD for gastrointestinal tumors in the
esophagus and stomach could be safely performed
with propofol-remifentanil analgosedation without
endotracheal intubation. There was no mortality as a
result of complications. Conversion to endotracheal
intubation took place in one patient only. Coughing
was observed in another patient, which brings the intra-
procedural anesthesia-related complication rate to
2.3%. Two other minor postprocedural complications
were observed that were not obviously anesthesia or
ESD related, without additional consequences for the
patient. No postprocedural anesthesia-related compli-
cations were observed. The intraprocedural ESD-
related complication rate was 3.4% and the postproce-
dural ESD-related complication rate was 15.9%. A
total of 93.2% of the patients were discharged the
same day or the day after the procedure.
Endoscopy-related complication rates in gastricESDs
range from 1.2% to 5.2% for perforation and 0% to
15.6% for delayed bleeding.26 In ESDs performed in
the esophagus, perforation ranges from 0% to 6.9%
and delayed bleeding ranges from 0% to 5.2%.27
Although no perforations occurred in our study, the
overall postprocedural ESD-related complication rate
was still 15.9%, which seems high compared with other
studies.However, in our series painwas also considered a
complication if this resulted in a longer hospital stay,
even one day after the procedure. When taking only per-
foration and delayed bleeding into consideration, in line
with what is reported in most studies, the ESD-related
complication rate is 9.1% (8/88). This includes only
bleeding in the stomach, which corresponds with the
reported range of 0% to 15.6% in the literature.26
Studies inwhich sedationmethodwas taken into account
reported low ESD-related complication rates during
ESD when general anesthesia was used. Song et al.12
reported a lower perforation rate in esophageal ESDs
in patients receiving general anesthesia compared with
those who received propofol sedation (1.2% vs 14.0%).
This reported perforation rate of 14.0%when using pro-
pofol sedation seems exceedingly high. No perforations
were reported in our study. Another study, using general
anesthesia, reported no ESD-related complications
during esophageal ESD and low complication rates in
gastric ESD (bleeding: 1.6% and perforation: 1.7%).7
To judge the safety of ESD in relation to the sed-
ation method used, it would be appropriate to focus
on anesthesia-related complications. Several studies
reported fewer anesthesia-related complications in
patients receiving general anesthesia during ESD.
In a study by Yurtlu et al.,23 cough was observed
more frequently during ESD in patients receiving pro-
pofol compared with general anesthesia (50% vs 5.4%).
Likewise, desaturation occurred more often in the pro-
pofol sedation group (18.5% vs 2.7%).23 In contrast,
we observed cough in only one patient (1.1%). This was
likewise for desaturation (1.1%). Other studies in
which general anesthesia were used during ESD in the
esophagus and stomach reported no hypotension,
desaturation or aspiration.7,28 We encountered no
hypotension or aspiration either.
The published literature to date indicates that, com-
pared with propofol sedation, the risk-beneﬁt balance is
in favor of general anesthesia. It is diﬃcult, however, to
discern to what extent the training and experience of
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the SP plays a decisive role in this equation. In our
setting, propofol sedation is managed by an SP, a
member of the anesthesiology department who is super-
vised by the anesthesiologist. Under these conditions,
the results of propofol sedation were excellent and only
one case required conversion to general anesthesia with
endotracheal intubation. Moreover, our anesthesia-
related complication rates are lower compared with
other studies in which hemodynamic events and
respiratory events during propofol sedation were
reported to be 37.3% and 14.1%, respectively.29
Another reported advantage of general anesthesia is a
shorter procedure time due to fewer interruptions during
ESD.28 In that particular study, however, the time
between insertion and withdrawal of the endoscope was
considered the ESD procedure time without including the
time the patient was in the operation room.28 Therefore,
the total procedure time including preparation for gen-
eral anesthesia might be much longer. The median ESD
procedure time in the study by Rong et al.,28 in which
general anesthesia was used, was 42.5 minutes compared
with 100 minutes in our study. This is a huge diﬀerence.
Rong and colleagues, however, excluded lesions >20mm
in contrast to a median lesion size of 30mm in our study,
which explains this diﬀerence. In the same study less
body movement and more comfort for the patient were
reported as other advantages of general anesthesia.28 In
our anesthesia reports, interruptions and body move-
ments were not reported, which precludes further quan-
titative analysis in our series. According to the SP (L.L.)
and the endoscopist (A.K.) who performed all the pro-
cedures, no procedure was interrupted because of patient
movements. In this retrospective study we could not
report on patient satisfaction after the procedure.
This study demonstrates the feasibility and safety of
propofol sedation for ESD. This was accomplished
with limited hospital admission time with 48.9% of
the patients being discharged the day of the procedure
and another 44.3% being discharged the day after the
procedure. In contrast, other studies in which general
anesthesia was used for ESD reported a mean hospital
stay of more than four days.7,12,23
Compared with propofol sedation, general anesthe-
sia requires additional facilities, more expertise, and an
anesthesiologist.28 Furthermore, most patients cannot
be discharged the same day when undergoing the pro-
cedure under general anesthesia, which results in a
longer hospital stay.7,12,23 Therefore, general anesthesia
in all likelihood results in higher costs, although formal
cost-eﬀectiveness studies are needed to quantify poten-
tial savings in a speciﬁc local setting.28
The main strength of this study is that all ESDs were
performed by the same endoscopist (A.K.) and by the
same sedation practitioner (L.L.), both with extensive
experience in this procedure. This limits confounding
factors such as experience and technical skills.
However, we are aware that such a dedicated team is
quite unique in the clinical routine. In particular, an SP
is not very common since an anesthesiologist is required
in most countries when propofol sedation is used.30
A second strength is that we included all consecutive
ESDs in the upper digestive tract between October 2013
and February 2018 performed with propofol sedation
regardless of location or size of the lesion.
Some limitations need to be discussed. This is a
retrospective, observational, single-center study, which
potentially limits the generalizability of our results.
There was no comparator group in our study, which
could be seen as a limitation. A randomized, controlled
trail in which propofol sedation (performed by an SP) is
compared with general anesthesia (performed by an
anesthesiologist) during ESD is needed to deﬁnitively
prove the safety of propofol sedation performed by an
SP. Owing to the retrospective nature of this study, we
did not know the exact number of interruptions during
ESD caused by restlessness of the patient. Patient sat-
isfaction could also not be assessed.
Conclusion
In conclusion, in this retrospective, observational,
proof-of-concept cohort study, propofol-remifentanil
analgosedation without endotracheal intubation
proved to be a feasible and safe sedation method for
ESD in the esophagus and stomach. Patients could be
discharged shortly after the procedure without readmis-
sion for anesthesia-related complications. In line with
these observations and logistical and ﬁnancial ramiﬁca-
tions, propofol-remifentanil analgosedation without
endotracheal intubation for ESD should be considered
over general anesthesia when a sedation practitioner is
available.
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